Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifoliaopen access
- Authors
- Kim, Dae Wook; Seo, Kyung Hye; Curtis-Long, Marcus J.; Oh, Kyeong Yeol; Oh, Jong-Won; Cho, Jung Keun; Lee, Kon Ho; Park, Ki Hun
- Issue Date
- Feb-2014
- Publisher
- INFORMA HEALTHCARE
- Keywords
- Mixed type I inhibition; papain-like protease inhibitor; Psoralea corylifolia; severe acute respiratory syndrome coronavirus papain-like protease
- Citation
- JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, v.29, no.1, pp 59 - 63
- Pages
- 5
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Volume
- 29
- Number
- 1
- Start Page
- 59
- End Page
- 63
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/19171
- DOI
- 10.3109/14756366.2012.753591
- ISSN
- 1475-6366
1475-6374
- Abstract
- Severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease (PLpro) is a key enzyme that plays an important role in SARS virus replication. The ethanol extract of the seeds of Psoralea corylifolia showed high activity against the SARS-CoV PLpro with an IC50 of value of 15 mu g/ml. Due to its potency, subsequent bioactivity-guided fractionation of the ethanol extract led to six aromatic compounds (1-6), which were identified as bavachinin (1), neobavaisoflavone (2), isobavachalcone (3), 4'-O-methylbavachalcone (4), psoralidin (5) and corylifol A (6). All isolated flavonoids (1-6) inhibited PLpro in a dose-dependent manner with IC50 ranging between 4.2 and 38.4 mu M. Lineweaver-Burk and Dixon plots and their secondary replots indicated that inhibitors (1-6) were mixed inhibitors of PLpro. The analysis of K-I and K-IS values proved that the two most promising compounds (3 and 5) had reversible mixed type I mechanisms.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.